• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CYP2B6 Gene Record

  • Summary
  • Interactions
  • Claims
  • CYP2B6 1555 Druggable Genome

    Alternate Names:

    1555
    CYTOCHROME P450 FAMILY 2 SUBFAMILY B MEMBER 6
    CYP2B6
    CPB6
    CYP2B
    CYP2B7
    CYP2B7P
    CYPIIB6
    EFVM
    IIB1
    P450
    123930
    2615
    ENSG00000197408
    OTTHUMG00000182714
    CYTOCHROME P450 2B6 (EC 1.14.14.1) (CYPIIB6) (P450 IIB1). [SOURCE:UNIPROT/SWISSPROT;ACC:P20813]
    PA123
    P20813
    CP2B6_HUMAN
    CYTOCHROME P450 2B6

    Gene Info:

    Human Readable Name DRUGGABLE GENOME
    Interpro Short Name Cyt_P450
    Interpro Acc IPR001128
    Interpro Name Cytochrome P450
    Uniprot Evidence 1: Evidence at protein level
    Uniprot Status Swiss-Prot
    Human Readable Name CYTOCHROME P450
    Interpro Type Family
    Gene Biotype PROTEIN_CODING
    (5 More Sources)

    Gene Categories: Category Details

    DRUGGABLE GENOME
    CYTOCHROME P450
    ENZYME

    Publications:

    Lang T et al., 2001, Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver., Pharmacogenetics
    Zanger UM et al., 2007, Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance., Pharmacogenomics
    Sridar C et al., 2012, Bioactivation of the cancer chemopreventive agent tamoxifen to quinone methides by cytochrome P4502B6 and identification of the modified residue on the apoprotein., Drug Metab Dispos
    D'Avolio A et al., 2013, Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane., Pharmacogenet Genomics
    Victorri-Vigneau C et al., 2019, Relevance of CYP2B6 and CYP2D6 genotypes to methadone pharmacokinetics and response in the OPAL study., Br J Clin Pharmacol
    Mactier H et al., 2017, Variations in Infant CYP2B6 Genotype Associated with the Need for Pharmacological Treatment for Neonatal Abstinence Syndrome in Infants of Methadone-Maintained Opioid-Dependent Mothers., Am J Perinatol
    Zahari Z et al., 2016, Relationship between CYP2B6*6 and cold pressor pain sensitivity in opioid dependent patients on methadone maintenance therapy (MMT)., Drug Alcohol Depend
    Csajka C et al., 2016, Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid-Dependent Patients., Clin Pharmacokinet
    Mouly S et al., 2015, Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity., Br J Clin Pharmacol
    Dobrinas M et al., 2013, Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study., Pharmacogenet Genomics
    Hung CC et al., 2011, Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients., Pharmacogenomics
    Levran O et al., 2013, CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction., Addict Biol
    Uehlinger C et al., 2007, Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients., J Clin Psychopharmacol
    Eap CB et al., 2007, Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers., Clin Pharmacol Ther
    Crettol S et al., 2006, ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment., Clin Pharmacol Ther
    Crettol S et al., 2005, Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment., Clin Pharmacol Ther
    Amunugama HT et al., 2012, Mechanism-based inactivation of cytochrome P450 2B6 by methadone through destruction of prosthetic heme., Drug Metab Dispos
    Jeong S et al., 2009, Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A., Antimicrob Agents Chemother
    Habtewold A et al., 2013, Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients., Pharmacogenomics J
    Gong L et al., 2017, PharmGKB summary: sorafenib pathways., Pharmacogenet Genomics
    Abell LM et al., 2011, Dissecting the activation of thienopyridines by cytochromes P450 using a pharmacodynamic assay in vitro., J Pharmacol Exp Ther
    Faucette et al., 2004, Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers., Drug Metab. Dispos.
    Gong L et al., 2014, PharmGKB summary: tramadol pathway., Pharmacogenet Genomics
    Wang Y et al., 2017, Association of CYP2B6 gene polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a Chinese population., Infect Genet Evol
    Cho DY et al., 2016, Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers., Drug Metab Pharmacokinet
    Garcia KL et al., 2015, Effect of Brain CYP2B Inhibition on Brain Nicotine Levels and Nicotine Self-Administration., Neuropsychopharmacology
    Ring HZ et al., 2007, Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism., Pharmacogenet Genomics
    Johnstone E et al., 2006, Determinants of the rate of nicotine metabolism and effects on smoking behavior., Clin Pharmacol Ther
    McKillop et al., 1998, Enzyme-inducing effects of bicalutamide in mouse, rat and dog., Xenobiotica
    Chang et al., 1993, Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes., Cancer Res.
    Chen et al., 2005, Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450., Drug Metab. Dispos.
    Braybrooke et al., 2005, Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma., Clin. Cancer Res.
    van Schaik, 2004, Implications of cytochrome P450 genetic polymorphisms on the toxicity of antitumor agents., Ther Drug Monit
    Kalra S et al., 2018, Association of CYP2C19*2 and ALDH1A1*1/*2 variants with disease outcome in breast cancer patients: results of a global screening array., Eur J Clin Pharmacol
    Shu W et al., 2017, Cytochrome P450 Genetic Variations Can Predict mRNA Expression, Cyclophosphamide 4-Hydroxylation, and Treatment Outcomes in Chinese Patients With Non-Hodgkin's Lymphoma., J Clin Pharmacol
    Veal GJ et al., 2016, Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma., Eur J Cancer
    Johnson GG et al., 2013, CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia., Blood
    Ariyoshi N et al., 2011, Q172H replacement overcomes effects on the metabolism of cyclophosphamide and efavirenz caused by CYP2B6 variant with Arg262., Drug Metab Dispos
    Bray J et al., 2010, Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide., Br J Cancer
    Rocha V et al., 2009, Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia., Leukemia
    May-Manke et al., 1999, Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N-dechloroethylation of trofosfamide., Cancer Chemother. Pharmacol.
    Dvorak et al., 2003, Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation., Mol. Pharmacol.
    Ciccacci C et al., 2017, Impact of glutathione transferases genes polymorphisms in nevirapine adverse reactions: a possible role for GSTM1 in SJS/TEN susceptibility., Eur J Clin Pharmacol
    Olagunju A et al., 2016, Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study., Pharmacogenet Genomics
    Ciccacci C et al., 2013, Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study., Eur J Clin Pharmacol
    Heil SG et al., 2012, Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals., Ther Drug Monit
    Lehr T et al., 2011, Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine., Pharmacogenet Genomics
    Gozalo C et al., 2011, Pharmacogenetics of toxicity, plasma trough concentration and treatment outcome with nevirapine-containing regimen in anti-retroviral-naïve HIV-infected adults: an exploratory study of the TRIANON ANRS 081 trial., Basic Clin Pharmacol Toxicol
    Yuan J et al., 2011, Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent., AIDS
    Chen J et al., 2010, CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients., Ther Drug Monit
    Ciccacci C et al., 2010, Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique., Pharmacogenomics
    Mahungu T et al., 2009, Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population., HIV Med
    Rotger M et al., 2005, Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients., Pharmacogenet Genomics
    Faucette et al., 2007, Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers., J. Pharmacol. Exp. Ther.
    Thorn CF et al., 2011, PharmGKB summary: carbamazepine pathway., Pharmacogenet Genomics
    Roy et al., 1995, Human liver oxidative metabolism of O6-benzylguanine., Biochem. Pharmacol.
    Kassogue Y et al., 2014, Functional polymorphism of CYP2B6 G15631T is associated with hematologic and cytogenetic response in chronic myeloid leukemia patients treated with imatinib., Med Oncol
    Jaquenoud Sirot E et al., 2012, Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression., J Clin Psychopharmacol
    Uppugunduri CR et al., 2014, The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation., Pharmacogenomics J
    Rendic et al., 1999, Metabolism of anabolic steroids by recombinant human cytochrome P450 enzymes. Gas chromatographic-mass spectrometric determination of metabolites., J. Chromatogr. B Biomed. Sci. Appl.
    Li Y et al., 2015, CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects., Br J Clin Pharmacol
    Yuce-Artun N et al., 2016, Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients., Int J Clin Pharm
  • TROFOSFAMIDE   CYP2B6

    Interaction Score: 2.58

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10447581


    Sources:
    NCI

  • KETAMINE   CYP2B6

    Interaction Score: 1.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25702819 11470993 17638512


    Sources:
    PharmGKB

  • MEPERIDINE   CYP2B6

    Interaction Score: 0.97

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11470993 17638512


    Sources:
    PharmGKB

  • NEVIRAPINE   CYP2B6

    Interaction Score: 0.9

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28689274 27195527 23774940 22354160 21860339 21824325 21505298 20625352 20017669 19228205 15864119 11470993 17638512 17041008


    Sources:
    NCI PharmGKB

  • METHADONE   CYP2B6

    Interaction Score: 0.78

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30907440 28320034 27289271 27286724 25556837 23249875 21902500 21790905 17502774 17329992 17178267 16338275 11470993 17638512 22685215


    Sources:
    DTC PharmGKB

  • ETHAMBUTOL   CYP2B6

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28389387


    Sources:
    PharmGKB

  • OSPEMIFENE   CYP2B6

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • ARTEMISININ   CYP2B6

    Interaction Score: 0.55

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11470993 17638512


    Sources:
    PharmGKB

  • 6-O-BENZYLGUANINE   CYP2B6

    Interaction Score: 0.52

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7503788


    Sources:
    NCI

  • PRASUGREL   CYP2B6

    Interaction Score: 0.48

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21828263


    Sources:
    PharmGKB FDA

  • IFOSFAMIDE   CYP2B6

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11470993 17638512


    Sources:
    PharmGKB

  • SELEGILINE   CYP2B6

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11470993 17638512


    Sources:
    PharmGKB

  • BICALUTAMIDE   CYP2B6

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9622849


    Sources:
    NCI

  • VORICONAZOLE   CYP2B6

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19029318


    Sources:
    DTC

  • MEPHENYTOIN   CYP2B6

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11470993 17638512


    Sources:
    PharmGKB

  • PYRAZINAMIDE   CYP2B6

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28389387


    Sources:
    PharmGKB

  • THIOTEPA   CYP2B6

    Interaction Score: 0.32

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    17638512


    Sources:
    PharmGKB

  • MITOTANE   CYP2B6

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23524664


    Sources:
    PharmGKB

  • RIFAMPIN   CYP2B6

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28389387 27053325 17638512


    Sources:
    PharmGKB

  • COTININE   CYP2B6

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18004205


    Sources:
    PharmGKB

  • ARTEMETHER   CYP2B6

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • CYCLOPHOSPHAMIDE   CYP2B6

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8242617 15919850 15746054 15228172 29938344 28181240 26773420 24128861 21821736 20179710 19005482 11470993 17638512


    Sources:
    NCI PharmGKB

  • TICLOPIDINE   CYP2B6

    Interaction Score: 0.2

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    17638512


    Sources:
    PharmGKB

  • ISONIAZID   CYP2B6

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28389387


    Sources:
    PharmGKB

  • CHEMBL530733   CYP2B6

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • EFAVIRENZ   CYP2B6

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17041008


    Sources:
    NCI FDA

  • STAVUDINE   CYP2B6

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23089673


    Sources:
    PharmGKB

  • NICOTINE   CYP2B6

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25652250 18004205 17015050 11470993 17638512


    Sources:
    PharmGKB

  • BUSULFAN   CYP2B6

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24165757


    Sources:
    PharmGKB

  • FLIBANSERIN   CYP2B6

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • TRAMADOL   CYP2B6

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24849324


    Sources:
    PharmGKB

  • CARBAMAZEPINE   CYP2B6

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14977870 21738081 17638512


    Sources:
    NCI PharmGKB

  • PHENOBARBITAL   CYP2B6

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14977870 17638512


    Sources:
    NCI PharmGKB

  • RITONAVIR   CYP2B6

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14977870


    Sources:
    NCI

  • MIRTAZAPINE   CYP2B6

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22926595


    Sources:
    PharmGKB

  • DIAZEPAM   CYP2B6

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11470993 17638512


    Sources:
    PharmGKB

  • SERTRALINE   CYP2B6

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26830411


    Sources:
    PharmGKB

  • MIDAZOLAM   CYP2B6

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11470993 17638512


    Sources:
    PharmGKB

  • LAMIVUDINE   CYP2B6

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23089673


    Sources:
    PharmGKB

  • ZIDOVUDINE   CYP2B6

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23089673


    Sources:
    PharmGKB

  • TESTOSTERONE   CYP2B6

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10630892


    Sources:
    NCI

  • PHENYTOIN   CYP2B6

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17638512


    Sources:
    PharmGKB

  • CLOPIDOGREL   CYP2B6

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • COLCHICINE   CYP2B6

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12815172


    Sources:
    NCI

  • TAMOXIFEN   CYP2B6

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22942317


    Sources:
    DTC

  • DOXORUBICIN   CYP2B6

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29938344 20179710


    Sources:
    PharmGKB

  • IMATINIB   CYP2B6

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24293093


    Sources:
    PharmGKB

  • SORAFENIB   CYP2B6

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28362716


    Sources:
    PharmGKB

  • Ensembl: ENSG00000197408

    • Version: 101_38

    Alternate Names:
    CYP2B6 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • RussLampel: ENSG00000197408

    • Version: 26-July-2011

    Alternate Names:
    CYP2B6 Display Id
    CYTOCHROME P450 2B6 (EC 1.14.14.1) (CYPIIB6) (P450 IIB1). [SOURCE:UNIPROT/SWISSPROT;ACC:P20813] Description
    ENSG00000197408 Ensembl Gene Id

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • HopkinsGroom: P20813

    • Version: 11-September-2012

    Alternate Names:
    ENSG00000197408 Ensembl Gene Id
    CYP2B6 Uniprot Gene Name
    P20813 Uniprot Accession

    Gene Info:
    Interpro Acc IPR001128
    Interpro Name Cytochrome P450
    Uniprot Evidence 1: Evidence at protein level

    Gene Categories:
    DRUGGABLE GENOME, CYTOCHROME P450

    Publications:

  • PharmGKB: CYP2B6

    • Version: 18-August-2020

    Alternate Names:
    PA123 PharmGKB ID

    Gene Info:

    Publications:
    Zanger UM et al., 2007, Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance., Pharmacogenomics
    Lang T et al., 2001, Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver., Pharmacogenetics
    Gong L et al., 2017, PharmGKB summary: sorafenib pathways., Pharmacogenet Genomics

  • NCI: CYP2B6

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    May-Manke et al., 1999, Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N-dechloroethylation of trofosfamide., Cancer Chemother. Pharmacol.
    Rendic et al., 1999, Metabolism of anabolic steroids by recombinant human cytochrome P450 enzymes. Gas chromatographic-mass spectrometric determination of metabolites., J. Chromatogr. B Biomed. Sci. Appl.
    Faucette et al., 2007, Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers., J. Pharmacol. Exp. Ther.

  • DTC: CYP2B6

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Jeong S et al., 2009, Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A., Antimicrob Agents Chemother
    Amunugama HT et al., 2012, Mechanism-based inactivation of cytochrome P450 2B6 by methadone through destruction of prosthetic heme., Drug Metab Dispos
    Sridar C et al., 2012, Bioactivation of the cancer chemopreventive agent tamoxifen to quinone methides by cytochrome P4502B6 and identification of the modified residue on the apoprotein., Drug Metab Dispos

  • HingoraniCasas: ENSG00000197408

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000197408 Gene Symbol
    CYP2B6 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • Pharos: CYP2B6

    • Version: 01-February-2022

    Alternate Names:
    Cytochrome P450 2B6 Gene Name
    P20813 UniProt ID

    Gene Info:

    Gene Categories:
    ENZYME

    Publications:

  • FDA: CYP2B6

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21